A Japan national funding agency has awarded $32 million to advance EPF-001, a treatment for sickle cell disease, into ...

As the season shifts from winter to spring, I’ve found myself reflecting deeply on what this past winter has meant for me. I’m incredibly grateful, and I know it didn’t happen by chance. It was the ...

A team of U.S. senators introduced new funding legislation for a stem cell transplant program for blood disorders like sickle ...

Watching for early signs and symptoms of a sickle cell crisis allows columnist Oluwatosin Adesoye to initiate timely ...

Adults with sickle cell disease are at a high risk of having a stroke in their 30s and 40s, with lasting physical disability, ...

A team of nurses led a project to standardize the emergency care received by patients with sickle cell disease (SCD), ...

The first participant with sickle cell disease (SCD) has been dosed in a clinical trial of HBI-002, an experimental, low-dose, oral liquid formulation of carbon monoxide being developed by Hillhurst ...

Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell disease (SCD). “This is a transformative time for Children’s ...

FTX-6058 is an experimental small molecule treatment for sickle cell disease (SCD) being developed by Fulcrum Therapeutics. It aims to treat patients by raising levels of fetal hemoglobin in cells.

Sickle cell disease (SCD) may be cured in some individuals by a stem cell transplant. There also are several approved therapies to help manage the condition and its related complications. Some of the ...

The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment Oxbryta (voxelotor) — withdrawn from the market ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The Centers for Medicare & Medicaid Services (CMS) has announced ...